Immunocore Holdings Plc (IMCR)
35.36
-0.77
(-2.13%)
USD |
NASDAQ |
Sep 08, 16:00
35.32
-0.04
(-0.11%)
After-Hours: 20:00
Immunocore Holdings Enterprise Value : 1.375B for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 1.375B |
| September 04, 2026 | 1.415B |
| September 03, 2026 | 1.489B |
| September 02, 2026 | 1.479B |
| September 01, 2026 | 1.452B |
| August 31, 2026 | 1.425B |
| August 28, 2026 | 1.440B |
| August 27, 2026 | 1.447B |
| August 26, 2026 | 1.466B |
| August 25, 2026 | 1.480B |
| August 24, 2026 | 1.439B |
| August 21, 2026 | 1.453B |
| August 20, 2026 | 1.422B |
| August 19, 2026 | 1.452B |
| August 18, 2026 | 1.409B |
| August 17, 2026 | 1.359B |
| August 14, 2026 | 1.316B |
| August 13, 2026 | 1.315B |
| August 12, 2026 | 1.343B |
| August 11, 2026 | 1.314B |
| August 10, 2026 | 1.304B |
| August 07, 2026 | 1.305B |
| August 06, 2026 | 1.331B |
| August 05, 2026 | 1.269B |
| August 04, 2026 | 1.266B |
| Date | Value |
|---|---|
| August 03, 2026 | 1.224B |
| July 31, 2026 | 1.295B |
| July 30, 2026 | 1.298B |
| July 29, 2026 | 1.275B |
| July 28, 2026 | 1.280B |
| July 27, 2026 | 1.293B |
| July 24, 2026 | 1.357B |
| July 23, 2026 | 1.383B |
| July 22, 2026 | 1.384B |
| July 21, 2026 | 1.330B |
| July 20, 2026 | 1.308B |
| July 17, 2026 | 1.354B |
| July 16, 2026 | 1.329B |
| July 15, 2026 | 1.340B |
| July 14, 2026 | 1.278B |
| July 13, 2026 | 1.227B |
| July 10, 2026 | 1.200B |
| July 09, 2026 | 1.258B |
| July 08, 2026 | 1.294B |
| July 07, 2026 | 1.274B |
| July 06, 2026 | 1.199B |
| July 02, 2026 | 1.228B |
| July 01, 2026 | 1.184B |
| June 30, 2026 | 1.189B |
| June 29, 2026 | 1.137B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Silence Therapeutics Plc | 495.01M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -18.96M |
| Mereo BioPharma Group Plc | 11.55M |
| Compass Pathways Plc | 1.526B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.8095M |
| Revenue (Quarterly) | 116.14M |
| Total Expenses (Quarterly) | 116.95M |
| EPS Diluted (Quarterly) | -0.0159 |
| Gross Profit Margin (Quarterly) | 98.18% |
| Profit Margin (Quarterly) | -0.70% |
| Earnings Yield | -1.05% |
| Normalized Earnings Yield | -1.600 |